Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.5B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be looking for improvements or declines compared to previous quarters.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's market performance and ability to sustain operations and fund future research.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetic diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape the future of medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Expectations for Cogent's upcoming earnings are mixed, with no analyst estimates available. Investors are particularly focused on whether the company can narrow its losses.

Bull Case

If Cogent can show a smaller loss than expected and provide positive commentary on future drug developments, it could boost investor confidence significantly.

Bear Case

Conversely, if the company reports a larger loss and lacks a clear path to profitability, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for upcoming drug trials?

The market will closely watch for any changes in timelines, as delays could signal deeper issues within the company.

How does management plan to address the recent EPS misses?

Investors need to understand the company's strategy for improving profitability, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Cogent to improve its EPS as it refines its drug pipeline and manages costs more effectively.

Supporting Evidence

The options market is pricing a 10.4% move, indicating expectations of significant volatility, which may not align with historical performance.

Cogent has shown resilience in stock price reactions despite EPS misses, suggesting investor patience could lead to future gains.

Key Risk

If the company reports an EPS loss narrower than expected, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to control costs and improve its financial outlook amid ongoing losses.

Bull Confirmed If

A narrower EPS loss than -$0.64 would indicate progress in cost management and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.64 could confirm ongoing financial struggles and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations and raises guidance, history suggests a positive reaction, averaging a +2.45% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted response.

Miss

If the company misses again, history suggests a potential decline, averaging a -3.44% move.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for drug trials and any new data from ongoing studies.
2Management's strategy for reducing costs and improving profitability.
3Any partnerships or collaborations that could enhance the company's market position.
4Insights into market demand for Cogent's therapies and how they plan to meet it.
5Details on cash burn and runway to gauge financial health moving forward.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

RecapView

Nov1

CNAReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be looking for improvements or declines compared to previous quarters.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's market performance and ability to sustain operations and fund future research.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Expectations for Cogent's upcoming earnings are mixed, with no analyst estimates available. Investors are particularly focused on whether the company can narrow its losses.

Bull Case

If Cogent can show a smaller loss than expected and provide positive commentary on future drug developments, it could boost investor confidence significantly.

Bear Case

Conversely, if the company reports a larger loss and lacks a clear path to profitability, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for upcoming drug trials?

The market will closely watch for any changes in timelines, as delays could signal deeper issues within the company.

How does management plan to address the recent EPS misses?

Investors need to understand the company's strategy for improving profitability, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Cogent to improve its EPS as it refines its drug pipeline and manages costs more effectively.

Supporting Evidence

The options market is pricing a 10.4% move, indicating expectations of significant volatility, which may not align with historical performance.

Cogent has shown resilience in stock price reactions despite EPS misses, suggesting investor patience could lead to future gains.

Key Risk

If the company reports an EPS loss narrower than expected, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to control costs and improve its financial outlook amid ongoing losses.

Bull Confirmed If

A narrower EPS loss than -$0.64 would indicate progress in cost management and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.64 could confirm ongoing financial struggles and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations and raises guidance, history suggests a positive reaction, averaging a +2.45% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted response.

Miss

If the company misses again, history suggests a potential decline, averaging a -3.44% move.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for drug trials and any new data from ongoing studies.
2Management's strategy for reducing costs and improving profitability.
3Any partnerships or collaborations that could enhance the company's market position.
4Insights into market demand for Cogent's therapies and how they plan to meet it.
5Details on cash burn and runway to gauge financial health moving forward.